Interferon beta-1b biosimilar - Amega Biotech/Actover Pharmaceutical

Drug Profile

Interferon beta-1b biosimilar - Amega Biotech/Actover Pharmaceutical

Alternative Names: Actoferon

Latest Information Update: 14 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amega Biotech
  • Developer Actover Pharmaceutical; Amega Biotech
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 14 Aug 2013 Investigation in Multiple sclerosis in Argentina (SC)
  • 01 Jan 2013 Launched for Multiple sclerosis in Iran (SC)
  • 20 Oct 2011 Actover Pharmaceutical initiates enrolment in a phase III trial for Multiple sclerosis in Iran (IRCT2013030512398N2)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top